Literature DB >> 31768918

Current Review of Implantable Cardioverter Defibrillator Use in Patients With Left Ventricular Assist Device.

Jacinthe Boulet1, Emmanuelle Massie1, Blandine Mondésert2,3, Yoan Lamarche4, Michel Carrier4, Anique Ducharme5,6.   

Abstract

PURPOSE OF REVIEW: While use of implantable cardioverter defibrillator (ICD) in patients with heart failure (HF) and reduced ejection fraction is recommended, their role in patients with left ventricular assist device (LVAD) remains controversial, especially with continuous flow (CF) devices. RECENT
FINDINGS: Ventricular arrhythmias (VA) in LVAD patients are frequent and associated with worse outcomes, especially postoperatively. Data on the role of ICDs in LVAD patients are scarce, based on case reports or small retrospective series. While the majority of LVAD patients currently have an ICD, it seems that some might not derive any benefit, with additional risks in terms of inappropriate shocks, psychological distress, and infections. Some CF-LVAD patients are at high risk of VA and hemodynamic collapse; under those circumstances, an ICD might provide benefits. A randomized-controlled trial of routine ICD implantation in CF-LVAD would be needed to clarify their impact on survival in low risk patients.

Entities:  

Keywords:  Arrhythmias; Heart failure; Implantable cardioverter defibrillator; Left ventricular assist device

Mesh:

Year:  2019        PMID: 31768918     DOI: 10.1007/s11897-019-00449-8

Source DB:  PubMed          Journal:  Curr Heart Fail Rep        ISSN: 1546-9530


  80 in total

1.  Long-term use of a left ventricular assist device for end-stage heart failure.

Authors:  E A Rose; A C Gelijns; A J Moskowitz; D F Heitjan; L W Stevenson; W Dembitsky; J W Long; D D Ascheim; A R Tierney; R G Levitan; J T Watson; P Meier; N S Ronan; P A Shapiro; R M Lazar; L W Miller; L Gupta; O H Frazier; P Desvigne-Nickens; M C Oz; V L Poirier
Journal:  N Engl J Med       Date:  2001-11-15       Impact factor: 91.245

2.  Rationale and design of the randomized prospective ATLAS study: Avoid Transvenous Leads in Appropriate Subjects.

Authors:  Blandine Mondésert; Jamil Bashir; François Philippon; Marc Dubuc; Guy Amit; Derek Exner; Jacqueline Joza; David H Birnie; Chris Lane; Bernice Tsang; Victoria Korley; Danna Spears; Andrea Ling; Angie Djuric; Eugene Crystal; Tom Hruczkowski; Jean-François Roux; Sandra Carroll; Vidal Essebag; Andrew D Krahn; Jeff S Healey
Journal:  Am Heart J       Date:  2018-10-09       Impact factor: 4.749

Review 3.  Ventricular arrhythmias after left ventricular assist device.

Authors:  Shashima Nakahara; Christopher Chien; Jill Gelow; Khidir Dalouk; Charles A Henrikson; James Mudd; Eric C Stecker
Journal:  Circ Arrhythm Electrophysiol       Date:  2013-06

4.  Predictors and Clinical Impact of Late Ventricular Arrhythmias in Patients With Continuous-Flow Left Ventricular Assist Devices.

Authors:  Vincent Galand; Erwan Flécher; Vincent Auffret; Stéphane Boulé; André Vincentelli; Camille Dambrin; Pierre Mondoly; Frédéric Sacher; Karine Nubret; Michel Kindo; Thomas Cardi; Philippe Gaudard; Philippe Rouvière; Magali Michel; Jean-Baptiste Gourraud; Pascal Defaye; Olivier Chavanon; Constance Verdonk; Walid Ghodbane; Edeline Pelcé; Vlad Gariboldi; Matteo Pozzi; Jean-François Obadia; Pierre-Yves Litzler; Frédéric Anselme; Gerard Babatasi; Annette Belin; Fabien Garnier; Marie Bielefeld; David Hamon; Costin Radu; Bertrand Pierre; Thierry Bourguignon; Romain Eschalier; Nicolas D'Ostrevy; Marie-Cécile Bories; Eloi Marijon; Fabrice Vanhuyse; Hugues Blangy; Jean-Philippe Verhoye; Christophe Leclercq; Raphaël P Martins
Journal:  JACC Clin Electrophysiol       Date:  2018-07-25

5.  Twelve hours of sustained ventricular fibrillation supported by a continuous-flow left ventricular assist device.

Authors:  Daniel B Sims; Gregg Rosner; Nir Uriel; José González-Costello; Frederick A Ehlert; Ulrich P Jorde
Journal:  Pacing Clin Electrophysiol       Date:  2011-06-16       Impact factor: 1.976

6.  Implantable defibrillator therapy for ventricular tachyarrhythmia in left ventricular assist device patients.

Authors:  Hanno Oswald; Claudia Schultz-Wildelau; Ajmal Gardiwal; Ulrich Lüsebrink; Thorben König; Anna Meyer; David Duncker; Maximilian A Pichlmaier; Gunnar Klein; Martin Strüber
Journal:  Eur J Heart Fail       Date:  2010-04-20       Impact factor: 15.534

7.  Left ventricular mechanical assist devices and cardiac device interactions: an observational case series.

Authors:  David Foo; Bruce D Walker; Dennis L Kuchar; Charles W Thorburn; Andre Tay; Christopher S Hayward; Peter Macdonald; Anne Keogh; Eugene Kotlyar; Philip Spratt; Paul Jansz
Journal:  Pacing Clin Electrophysiol       Date:  2009-07       Impact factor: 1.976

8.  No Electromagnetic Interference Occurred in a Patient with a HeartMate II Left Ventricular Assist System and a Subcutaneous Implantable Cardioverter-Defibrillator.

Authors:  Ajay Sundara Raman; Farshad Raissi Shabari; Biswajit Kar; Pranav Loyalka; Ramesh Hariharan
Journal:  Tex Heart Inst J       Date:  2016-04-01

9.  Heart failure–associated hospitalizations in the United States.

Authors:  Saul Blecker; Margaret Paul; Glen Taksler; Gbenga Ogedegbe; Stuart Katz
Journal:  J Am Coll Cardiol       Date:  2013-03-26       Impact factor: 24.094

10.  Ventricular arrhythmias and implantable cardioverter-defibrillator therapy in patients with continuous-flow left ventricular assist devices: need for primary prevention?

Authors:  Arthur R Garan; Melana Yuzefpolskaya; Paolo C Colombo; John P Morrow; Rosie Te-Frey; Drew Dano; Hiroo Takayama; Yoshifumi Naka; Hasan Garan; Ulrich P Jorde; Nir Uriel
Journal:  J Am Coll Cardiol       Date:  2013-05-02       Impact factor: 24.094

View more
  2 in total

1.  Awake and aware with ongoing ventricular fibrillation during LVAD treatment: is it possible?

Authors:  Ingrid Hell Mott; Steen Hvitfeldt Poulsen; Brian Bridal Løgstrup
Journal:  BMJ Case Rep       Date:  2020-04-22

2.  Eligibility for subcutaneous implantable cardioverter-defibrillator in patients with left ventricular assist device.

Authors:  Christos Zormpas; Jörg Eiringhaus; Henrike A K Hillmann; Stephan Hohmann; Johanna Müller-Leisse; Jan D Schmitto; Christian Veltmann; David Duncker
Journal:  J Interv Card Electrophysiol       Date:  2020-07-01       Impact factor: 1.900

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.